Sponsor Dossier
Juno Pharmaceuticals
Sponsor Dossier for Juno Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADENOSINE
- Brand: ADRENALINE
- Brand: AMIODARONE
- Brand: AMOXICLAV JUNO
- Brand: ANIDULAFUNGIN
- Brand: APO-PALONOSETRON
- Brand: ARSENIC
- Brand: ATROPINE JUNO
- Device (sponsor): Syringe-loaded injector, manual, home-use
- Device (sponsor): IALURIL Procedure pack - Bladder instillation, barrier
- Device (sponsor): Urethral intravesical infusion tip
- Device (sponsor): IALURIL Prefill - Bladder instillation, barrier
- Device (sponsor): Adaptor, luer
About
Juno Pharmaceuticals is an Australian Private Company with ABN 55156303650, registered in Victoria. The entity is active and registered for GST from 2012.
Portfolio
Juno Pharmaceuticals has 98 brands on the ARTG, of which 70 are indexable. The portfolio includes 63 brands with Product Information on file. Thirteen brands have at least one PBS-listed item, 5 brands have PBAC outcomes on record, and 1 brand has an AusPAR on record.
Therapeutic focus
The portfolio is distributed across the following therapeutic areas: — Oncology: 27 brands — Infectious Disease: 21 brands — Pain & Anaesthesia: 16 brands — Cardiology: 11 brands — Neurology: 6 brands — Haematology: 3 brands — Gastroenterology: 3 brands — Women's Health: 2 brands — Ophthalmology: 2 brands — Psychiatry: 2 brands — Respiratory: 1 brand — Immunology: 1 brand — Endocrinology: 1 brand — Musculoskeletal: 1 brand — Other: 1 brand
PBS footprint
Thirteen brands in the Juno Pharmaceuticals portfolio have at least one PBS-listed item. The latest PBS schedule date the portfolio touched is 1 May 2026.
Regulatory activity
Juno Pharmaceuticals has 5 brands with PBAC outcomes on record, with the latest outcome dated 1 November 2021. The portfolio includes 1 brand with an AusPAR on record, dated 27 June 2023.